Israeli psychedelics biotech Clearmind Medicine (NASDAQ: CMND) has inked a research agreement with Johns Hopkins University School of Medicine (JHU) to conduct the first-in-human Phase I/IIa clinical trial on its proprietary MEAI-based compound CMND-100 for the potential treatment of Alcohol Use Disorder (AUD.) 

Associate psychiatry and behavioral sciences professor at JHU, Jennifer Ellis Ph.D. will be the study’s PI, seconded by the university’s behavioral pharmacology research unit director Prof. Eric Strain.

See Also: Johns Hopkins Researchers Find Psychedelics Reopen The Social Reward Learning Period

CEO Dr. Adi Zuloff-Shani says the team is honored and grateful to collaborate with JHU, “one of the global leaders in psychedelics clinical research and in researching addictions,” toward studying proprietary CMND-100 …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.